AXL is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain AXL status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].

AXL is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain AXL status and cancer as inclusion criteria, 2 are phase 1 (1 open) [4].

AXL is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AXL status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains AXL status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains AXL status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains AXL status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AXL is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains AXL status and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [4].